2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2649

“Point of Care” Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NPSLE)
Abstract Number: 2435

‘It’s like the Worst Toothache You’ve Ever Had’ – How Persons with Rheumatoid Arthritis Describe and Manage Pain in Daily Life
Abstract Number: L18

14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Abstract Number: 408

14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
Abstract Number: 359

14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Abstract Number: 362

14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Abstract Number: 405

14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
Abstract Number: 658

17β Estradiol Regulates VCAM-1 Expression during Glomerulonephritis
Abstract Number: 465

18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
Abstract Number: 2751

18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
Abstract Number: 667

24-Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings
Abstract Number: 1166

5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany
Abstract Number: 360

88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Abstract Number: 885

A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration
Abstract Number: 776

A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA

1
2
3
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].